← Back to Search

Monoclonal Antibodies

IMC-F106C Combinations for Solid Cancers

Phase 1 & 2
Recruiting
Research Sponsored by Immunocore Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2 years
Awards & highlights

Study Summary

This trial is designed to see if a new T cell receptor, IMC-F106C, is safe and effective in treating patients with cancer that is positive for the tumor-associated antigen PRAME.

Who is the study for?
This trial is for adults with solid tumors that have relapsed, are resistant to standard therapy, or can't tolerate it. Participants must test positive for HLA-A*02:01 and PRAME in their tumors and agree to use effective contraception if applicable. They should be able to consent and follow the study's rules but can't join if they have serious heart, lung, autoimmune diseases, transplants, active hepatitis B/C, HIV, significant other cancers or allergies related to the study drugs.Check my eligibility
What is being tested?
The trial tests IMC-F106C alone and combined with cancer treatments like atezolizumab (a checkpoint inhibitor), pembrolizumab (another checkpoint inhibitor), chemotherapy or tebentafusp. It aims to see how safe and effective these combinations are against cancers that show a specific antigen called PRAME.See study design
What are the potential side effects?
Possible side effects include reactions related to the immune system attacking normal cells by mistake which could lead to inflammation in various organs. There might also be typical drug infusion reactions such as fever or chills; fatigue; digestive issues; blood-related problems; increased risk of infections.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1: Incidence of adverse events (AE) and serious adverse events (SAE)
Phase 1: Incidence of dose-limiting toxicity (DLT)s
Phase 1: Mean change from baseline in QTcF interval
+7 more
Secondary outcome measures
Changes in lymphocyte counts over time
Changes in serum cytokines over time
Duration of response (DOR)
+9 more

Trial Design

5Treatment groups
Experimental Treatment
Group I: IMC-F106C and Targeted TherapyExperimental Treatment3 Interventions
Participants receive IMC-F106C and a selected targeted therapy. Receipt of kinase inhibitor is dependent on histology.
Group II: IMC-F106C and Multimodal TherapyExperimental Treatment1 Intervention
Participants receive IMC-F106C, biologics (eg, pembrolizumab, bevacizumab) IV infusions and chemotherapy IV infusions based on histology.
Group III: IMC-F106C and ChemotherapyExperimental Treatment1 Intervention
Participants receive IMC-F106C and chemotherapy. Choice of chemotherapy is dependent on cohort.
Group IV: IMC-F106C and Anti-PD(L)1 AgentExperimental Treatment1 Intervention
Participants receive IMC-F106C and pembrolizumab.
Group V: IMC-F106C MonotherapyExperimental Treatment1 Intervention
Participants receive IMC-F106C.

Find a Location

Who is running the clinical trial?

Immunocore LtdLead Sponsor
13 Previous Clinical Trials
3,042 Total Patients Enrolled
Shaad Abdullah, MDStudy DirectorImmunocore Ltd
1 Previous Clinical Trials
29 Total Patients Enrolled
Shaad Abdullah, MD, FACPStudy DirectorImmunocore Ltd

Media Library

IMC-F106C (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04262466 — Phase 1 & 2
Solid Tumors Research Study Groups: IMC-F106C Monotherapy, IMC-F106C and Chemotherapy, IMC-F106C and Anti-PD(L)1 Agent, IMC-F106C and Multimodal Therapy, IMC-F106C and Targeted Therapy
Solid Tumors Clinical Trial 2023: IMC-F106C Highlights & Side Effects. Trial Name: NCT04262466 — Phase 1 & 2
IMC-F106C (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04262466 — Phase 1 & 2
Solid Tumors Patient Testimony for trial: Trial Name: NCT04262466 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the cap on participant enrollment in this research endeavor?

"Immunocore Ltd is the sponsor of this trial, which requires 170 qualified participants. Memorial Sloan Kettering in New york and Thomas Jefferson University Hospital in Philadelphia are two locations where patients can be treated."

Answered by AI

How many medical facilities are conducting this investigation concurrently?

"Nine clinical trial sites are currently recruiting patients for this medical research, located in New york City, Philadelphia and Houston amongst other cities. It is suggested that participants select the nearest location to reduce their commute when possible."

Answered by AI

Is enrollment for this experiment still open?

"Per the documentation on clinicaltrials.gov, this research study is currently seeking participants. It was initially listed on February 25th 2020 and has been revised as recently as March 10th 2022."

Answered by AI

Who else is applying?

What state do they live in?
Washington
What site did they apply to?
University of Washington - Fred Hutchinson Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

Looking for alternative treatment.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
2020. "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04262466.
~242 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top